Abstract
The M1 muscarinic agonists AF102B (Cevimeline, EVOXACTM: prescribed in USA and Japan for Sjogren’s Syndrome), AF150(S) and AF267B—1) are neurotrophic and synergistic with neurotrophins such as nerve growth factor and epidermal growth factor; 2) elevate the non-amyloidogenic amyloid precursor protein (α-APPs) in vitro and decrease β-amyloid (Aβ) levels in vitro and in vivo; and 3) inhibit Aβ- and oxidative-stress-induced cell death and apoptosis in PC12 cells transfected with the M1 muscarinic receptor. These effects can be combined with the beneficial effects of these compounds on some other major hallmarks of Alzheimer’s disease (AD) (e.g. τ hyperphosphorylation and paired helical filaments [PHF]; and loss of cholinergic function conducive to cognitive impairments.) These drugs restored cognitive impairments in several animal models for AD, mimicking different aspects of AD, with a high safety margin (e.g. AF150[S] >1500 and AF267B >4500). Notably, these compounds show a high bioavailability and a remarkable preference for the brain vs. plasma following po administration. In mice with small hippocampi, unlike rivastigmine and nicotine, AF150(S) and AF267B restored cognitive impairments also on escape latency in a Morris water maze paradigm in reversal learning. Furthermore, in aged and cognitively impaired microcebes (a natural animal model that mimics AD pathology and cognitive impairments), prolonged treatment with AF150(S) restored cognitive and behavioral impairments and decreased τ hyperphosphorylation, PHF and astrogliosis. Our M1 agonists, alone or in polypharmacy, may present a unique therapy in AD due to their beneficial effects on major hallmarks of AD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beach T. G., Walker D. G., Potter P. E., and Fisher A. (2001) Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists, Brain Res. 905, 220–223.
Bons N., Jallageas V., Maestre-Frances N., Silhol S., Petter A., and Delacourte A. (1995) Microcebus murinus, a convenient laboratory animal for the study of Alzheimer’s disease. Alzheimer’s Res. 1, 83–87.
Buxbaum J. D., Oishi M., Chen H. I., Pinkas-Kramarski R., Jaffe E. A., Gandy S. E., and Greengard P. (1992) Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta-A4 amyloid protein precursor. Proc. Natl. Acad. Sci. USA 89, 10075–10078.
Eckols K., Bymaster F. P., Mitch C. H., Shannon H. E., Ward J. S., and DeLapp, N. W. (1995) The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from CHO M1 cells. Life Sci. 57, 1183–1190.
Farber S. A., Nitsch R. M., Schulz J. G., and Wurtman R. J. (1995) Regulated secretion of β-amyloid precursor protein in rat brain. J. Neurosci. 15, 7442–7451.
Fisher A. (1997) Muscarinic agonists for the treatment of Alzheimer’s disease: progress and perspectives. Exp. Opin. Invest. Drugs 6, 1395–1141.
Fisher A., Haring R., Pittel Z., Brandeis R., Eshhar N., Karton Y., et al. (1998) Novel therapeutic avenues in Alzheimer’s Disease based on M1 muscarinic agonists—a unifying concept. Int. J. Geriatric Psychopharmacol. 1, 150–157.
Fisher A. (1999) Muscarinic receptor agonists in Alzheimer’s disease. More than just symptomatic treatment. CNS Drugs 12, 197–214.
Fisher A., Brandeis R., Chapman Pittel Z., and Michaelson D. M. (1998) M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice. J. Neurochem. 70, 1991–1997.
Fisher, A. (2000) Therapeutic strategies in Alzheimer’s Disease: M1 muscarinic agonists. Jap. J. Pharmacol. 84, 101–112.
Forlenza O. V., Spink J. M., Dayanandan R., Anderton B. H., Olensen O. F., and Lovestone S. (2000) Muscarinic agonists reduce τ phosphorylation in non-neuronal cells via GSK-3β inhibition and in neurons. J. Neural. Transm. 107, 1201–1212.
Genis I., Fisher A., and Michaelson D. M. (1999) Site specific dephosphorylation of tau in apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment. J. Neurochem. 12, 206–213.
Giannakopoulos P., Silhol S., Jallageas V., Mallet J., Bons N., Bouras C., and Delaere P. (1997) Quantitative analysis of tau protein-immunoreactive accumulations and beta-amyloid protein deposits in the cerebral cortex of the mouse lemur, Microcebus murinus. Acta Neuropathol. 94, 131–139.
Gurwitz D., Haring R., Pinkas-Kramarski R., Stein R., Heldman E., Karton Y., and Fisher A. (1995) NGF-dependent neurotrophic-like effects of AF102B, an M1 muscarinic agonist, in PC12M1 cells. NeuroReport 6, 485–488.
Haring R., Gurwitz D., Barg J., Pinkas-Kramarski R., Heldman E., Pittel Z., et al. (1994) Amyloid precursor protein secretion via muscarinic receptors: Reduced desensitization using the M1-selective agonist AF102B. Biochem Biophys Res. Comm. 203, 652–658.
Haring R., Gurwitz D., Barg J., Pinkas-Kramarsky R., Heldman E., Pittel Z., et al. (1995) NGF promotes amyloid protein secretion via muscarinic receptor activation. Biochem. Biophys. Res. Comm. 213, 15–23.
Haring R., Pittel Z., Eizenberg O., and Fisher A. (2000) M1 muscarinic agonists protect PC12M1 cells from growth factor deprivation and beta-amyloid- induced apoptosis. World Conf. on AD: Washington DC, July 9–13.
Haring R., Fisher A., Marciano D., Pittel Z., Kloog Y., Zuckerman A., Eshhar N., and Heldman E. (1998) Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the M1 muscarinic receptor to amyloid precursor protein secretion. J. Neurochem. 71, 2094–2103.
Hellstrom-Lindahl E., Moore H., and Nordberg A. (2000) Increased levels of τ protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J. Neurochem. 74, 777–784.
Hock C., Maddalena A., Heuser I., Naber D., Oertel W., von Der Krame H., et al. (2000) Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer’s disease. Ann. NY Acad. Sci. 920, 285–291.
Hung A. Y., Haass C., Nitsch R., Qiu W. Q., Citron M., Wurtman R. J., Growdon J. H., and Selkoe D. J. (1993) Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J. Biol. Chem. 268, 22959–22962.
Kelly J. F., Furukawa K., Barger S. W., Rengen M. R., Mark R. J., Blanc E. M., et al. (1996) Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc. Natl. Acad. Sci. 96, 6753–6758.
Ladner C. J. and Lee J. M. (1998) Pharmacological drug treatment of Alzheimer disease: the cholinergic system revisited. J. Neuropathol. Exp. Neurol. 57, 719–731.
Leloup C., Michaelson D. M., Fisher A., Hartmann T., Beyreuther K., and Stein R. (2000) M1 muscarinic receptors blocks caspase activation by phosphatidylinositide 3-kinase and MAPK/ERK-independent pathways. Cell Death Diff. 7, 825–833
Lucas J., Hernandez F., Gomez-Ramos P., Moran M. A., Hen R., and Avila J. (2001) Decreased nuclear β-catenin, τ hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. 20, 27–39.
Mattson M. P. (1997) Central role of oxyradicals in the mechanism of amyloid beta-peptide cytotoxicity. Alzheimer’s Dis. Rev. 2, 1–14.
Muller D. M., Mendla K., Farber S. A., and Nitsch R. M. (1997) Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci. 60, 985–991.
Nitsch R. N., Slack B. E., Wurtman R. J., and Growdon J. H. (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 58, 304–307.
Nitsch R. M., Deng M., Tennis M., Schoenfield D., and Growdon, J. H. (2000) The selective muscarinic M1 agonist AF102B decreases levels of total A (beta) in cerebrospinal fluid of patients with Alzheimer’s disease. Ann. Neurol. 48, 913–918.
Pavia J., de Ceballos M., and de la Cuesta F. S. (1998) Alzheimer’s disease: relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins. Fundam. Clin. Pharmacol. 12, 473–481.
Perry E., Court J., Goodchild R., Griffiths M., Jaros E., Johnson M., et al. (1998) Clinical neurochemistry: developments in dementia research based on brain bank material. J. Neural Transm. 105, 915–933.
Pittel Z., Heldman E., Barg J., Haring R., and Fisher A. (1996) Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum. Brain Res. 742, 299–304.
Pittel Z., Haring R., Natan N., Marcovitch I., and Fisher A. (2000). Beta-amyloids (Aβ) impair M1 muscarinic receptor-mediated signaling yet Aβ-induced cell death is attenuated by M1 agonists. Soc. Neurosci. Abstr.
Sadot E., Gurwitz D., Barg J., Behar L., Ginzburg I., and Fisher A. (1996) Activation of m1-muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J. Neurochem. 66, 877–880.
Schwarz R. D., Callahan M. J., Davis R. E., Jaen J. C., and Tecle H. (1997) Development of M1 subtype selective muscarinic agonists for Alzheimer’s disease: translation of in vitro selectivity into in vivo efficacy. Drug Dev. Res. 40, 133–143.
Silhol S., Calenda A., Jallageas V., Mestre-Frances N., Bellis M., and Bons N. (1996) Beta-amyloid protein precursor in Microcebus murinus: genotyping and brain localization. Neurobiol. Dis. 3, 169–182.
Svensson A. L., Alafuzoff I., and Nordberg A: (1992) Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. Brain Res. 596, 142–148.
Vincent G. P. and Sepinwall J. (1992) AF102B, a novel M1 agonist, enhanced spatial learning in C57BL/10 mice with a long duration of action. Brain Res. 597, 264–268.
Wolf B. A., Wertkin A. M., Jolly Y. C., Yasuda R. O., Wolfe B. B., Konrad R. J., et al. (1995) Muscarinic regulation of Alzheimer’s disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. J. Biol Chem. 270, 4916–4922.
Yan X.-Z., Xiao R., Dou Y., Wang S.-D., Qiao Z.-D., and Qiao J.-T. (2000) Carbachol blocks beta-amyloid fragment 31–35-induced apoptosis in cultured cortical neurons. Brain Res. Bull. 51, 465–470.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fisher, A., Brandeis, R., Bar-Ner, R.H.N. et al. AF150(S) and AF267B. J Mol Neurosci 19, 145–153 (2002). https://doi.org/10.1007/s12031-002-0025-3
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s12031-002-0025-3